Muscle-specific inositide phosphatase (MIP/MTMR14) is reduced with
                        age and its loss accelerates skeletal muscle aging process by altering
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Aging is a complex biological process marked by the 
gradual decline of a multitude of physiological 
processes/functions that ultimately results in death [1-
5]. Normal aging results in sarcopenia, the decreased 
muscle mass and function that develops despite 
interventions such as increased physical activity and 
improved diet [6,7].  While these interventions have 
proven to be effective in ameliorating the loss of muscle 
function with age, there is no intervention that can 
completely prevent or reverse sarcopenia. 
 
The decline in muscle function (force and power) that 
results from sarcopenia is a major cause of restricted 
activity, muscle injuries, and loss of independence in 
older individuals. As populations age and live longer, 
this problem will continue to grow. The world wide 
cost of managing the consequences of sarcopenia is 
astronomical estimated in the hundreds of billions of 
dollars. Research designed to reveal the cellular 
mechanisms that contribute to sarcopenia and other age-
related muscle disorders is essential for the 
development of effective treatments that can improve 
health outcomes for older adults.  
 
It has been shown that the decrease in force and power 
that functionally characterize sarcopenia cannot be 
completely explained by atrophy alone [4,8,9]. Some of 
the mechanisms suggested to explain the discrepancy 
between atrophy-dependent vs. atrophy-independent 
loss of muscle function in aging include decreased 
myosin force and/or actin-myosin cross-bridge stability 
[8,9] and defective excitation-contraction coupling 
(ECC) [4;10]. Our research groups have contributed to 
the field of muscle aging by demonstrating that specific 
aspects of the excitation-contraction coupling (ECC) 
process are compromised with age [11,12].   
 
While aging is a multigene phenomenon [13-15], we 
have focused our most recent studies on a new protein, 
muscle-specific inositide phosphatase (MIP), also 
known as myotubularin-related protein 14 (MTMR14) 
[16]. In a recent report, we characterized its basic 
functions in skeletal muscle [16]. Our studies showed 
that MIP is important in the ECC process of skeletal 
muscle (particularly influencing store-operated calcium 
entry (SOCE), calcium (Ca
2+) storage and Ca
2+ release 
from the sarcoplasmic reticulum (SR).   
 
In the current study, we have used a combination of 
approaches to phenotypically compare mature mice 
lacking MIP (MIPKO) with old wild type (Wt) mice. 
We also measured the cellular expression, 
concentration, and activity of MIP within muscle fibers 
with age.  These findings were correlated with 
functional outcomes and revealed that key features of 
sarcopenia manifest in the MIPKO much earlier (12-14 
months) than in wild-type mice (22-24 months). The 
significant decrease in MIP mRNA expression, MIP 
protein content and MIP activity in normal, old Wt mice 
along with the striking phenotypic similarities between 
mature MIPKO and old Wt mice, suggest a putative role 




In vivo studies of activity: young and mature 
MIPKO mice behave like old WT mice 
 
 In our recently published study [16], we showed that 
in a rotarod function test, the latency of MIPKO mice 
to fall off the rotating rod was decreased. In the 
inclined screen test, the percentage of MIPKO mice 
that could reach to the top of the inclined screen was 
greatly decreased compared to that of Wt littermates. 
These findings are very similar to results obtained in 
old Wt mice. To broaden the phenotypic comparison 
between MIPKO and Wt mice, we used the force-plate 
actimeter measurements [17]. All mice tested 
remained in the actimeter for 40 min, and we found 
that young Wt mice (4-6 month, n=58) walked 280 ± 
27 meters, mature Wt (12-14 month, n=20) walked 
283 ± 23 meters, and old Wt (22-24 month, n=12) 
walked 175 ± 32 meters. In contrast, young MIPKO 
mice (4-6 month, n = 12) walked 240 ± 18 meters, 
mature MIPKO walked 200 ± 22 (12-14 month, n=12), 
and old MIPKO (18-20 month, n=12) walked 155 ± 13 
meters. These studies show that mature MIPKO mice 
behave like old Wt mice with respect to levels of 
spontaneous physical activity. 
 
Treadmill stress test reveals additional similarities 
between the mature MIPKO and old Wt mice 
  
These series of experiments were designed to test the 
effects of stress of running until exhaustion in a 
treadmill. Thus, untrained Wt and MIPKO mice were 
ran in a rodent treadmill until exhausted as previously 
described by our group [18]. The differences we found 
were dramatic. Young (n =12), mature (n = 18), and 
old Wt (n = 12) respectively ran 33 ± 5, 38 ± 3, and 13 
± 5 min. In contrast, young (n =12), mature (n = 18), 
and old MIPKO (n = 12) respectively ran 22 ± 4, 10 ± 
3, and 8 ± 5 min. These results are very intriguing, 
particularly when we contrasted the average running 
time of ~10 min in mature MIPKO mice with the 
running time of old (22-24 month) Wt mice of 13 ± 5 
min. These results strongly suggest that locomotor 
dysfunction has an earlier onset in MIPKO mice. 
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between mature MIPKO mice and old Wt littermates. 
We have also consistently observed that at this age, 
MIPKO mice are significantly less active in their cages 
as further substantiated by our actimeter studies. 
 
Accelerated muscle wasting in MIPKO mice might 
explain defective in vivo function and suggest earlier 
onset of sarcopenia 
 
We previously demonstrated that an 18-month old MIP 
KO mouse has ~40-50% less body mass as compared to 
the Wt littermates (See Figure 2 of our recent 
publication [16]). As seen in Figure 1, we now show 
that hindlimb muscle mass is also significantly reduced 
in the MIPKO mice when compared with Wt 
littermates, suggesting premature development of 
sarcopenia when MIP is ablated. These data might also 
help in explaining the reduced physical vigor 
























Contractile force and power generation are reduced 
in skeletal muscles from mature MIPKO in a fashion 
similar to that of old Wt mouse 
 
A functional corollary of sarcopenia in humans is the 
presence of decreased force and power. Figure 2A 
illustrates that the cross sectional area of skeletal muscle 
fibers from old Wt and mature MIPKO mice is reduced 
compared with mature Wt mice.  Figures 2B and 2D 
illustrate that the maximal contractile force and power 
in old Wt, mature MIPKO, and old MIPKO mice are 
significantly reduced from values found in mature Wt 
mice.  Atrophy can account for a reduction in force and 
power of approximately 25% (the dotted line in Figures 
2B  and  2D) in the old and MIPKO animals.  When 
maximal force and power are normalized to cross 
sectional area (Figures 2C and 2E), it is clear that there 
is a reduction in force and power that are independent of 
muscle wasting and result from changes in the 
contractile properties of the muscle fibers. Strikingly, 
the same functional changes that manifest at 24 months 
in muscles from old Wt mice manifest by 12 months of 
age in MIPKO mice, suggesting that MIP is an 
important modulator of contractile function during 
aging. 
 
Downregulation of MIP expression and function 
with normal muscle aging 
            
Figure 3 shows down-regulation of MIP in Wt mice 
during aging using 3 different approaches (MIP gene 
expression, MIP protein content, and MIP phosphatase 
activity). These data show that MIP is tightly regulated 
at all levels, from transcription to translation to activity 
levels, suggesting an important physiological role for 
this muscle phosphatase. These data also provide strong 
evidence for the involvement of MIP in the 
development of sarcopenia.  
 
Dysfunctional Ca
2+ homeostasis in old WT and 
mature MIPKO 
  
Figure 4 shows that Ca
2+ homeostasis is disrupted in 
both old Wt and mature MIPKO FDB muscle fibers. 
Three key features of intracellular Ca
2+ homeostasis 
were similarly affected by old age and MIP ablation. 
First, resting levels of Ca
2+ were higher in old Wt and 
MIPKO muscle fibers. Second, SR Ca
2+ release 
triggered by caffeine was reduced in muscle fibers 
from both old Wt and mature MIPKO mice. Third, 
while the Ca
2+ transient has a fast relaxation recovery 
in young Wt, it is significantly delayed in old Wt and 
MIPKO. We previously showed that intracellular 
elevation of PI(3,5)P2 due to the absence of MIP (see 
Figure 5) led to chronic activation of the ryanodine 
receptor (RyR1) and inhibition of store-operated Ca
2+ 
entry (SOCE) [16], which supports the present 
findings of altered Ca
2+ homeostasis with age or in the 
MIPKO subjects when MIP is downregulated and 
therefore PI(3,5)P2 is elevated. Undoubtedly, with 
chronic activation of the RyR1 by PI(3,5)P2, one 
predicts that resting levels of Ca
2+ will be higher and 
Ca
2+ storage and Ca
2+  transients reduced. This 
combination of effects is certainly detrimental to 
skeletal muscle function and will contribute to the 



































































































































































This communication and our previous study [16] 
elevate the role of MIP as a potent regulator of skeletal 
muscle function under normal conditions. The fact that 
MIP expression, concentration, and function are 
decreased with age also shows that MIP is important 
for, or at least contributes to, the development of 
sarcopenia. Furthermore, we have demonstrated that 
PI(3,5)P2 is the major substrate for MIP and that 
reduction in MIP levels leads to accumulation of 












































Thus, the significant decrease in MIP phosphatase 
activity during aging should induce accumulation of 
intracellular PI(3,5)P2, leading to Ca
2+ homeostasis 
defects, which is precisely the phenotype identified in 
both old Wt and mature MIPKO muscle fibers. 
  
Phospholipids and phosphoinosites were once thought 
to play only structural and energetic functions. They are 
now recognized as signaling molecules, particularly as 
second messengers [19-26]. PI(3,5)P2, discovered only 
10 years ago, is an isomer of the well-characterized 
phosphoinosite, PI(4,5)P2. PI(4,5)P2 has been exten-
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many membrane channels. The seven known PIPs (see 
Figure 5) are thought to form complex signal 
transduction networks in organisms spanning yeasts to 
humans. The broadness of cellular functions controlled 
and modulated by lipids seems almost unlimited with 
defined roles in cell signal transduction, proliferation, 
growth, apoptosis, immune response, and adaptation to 


































Each PIP binds to a distinctive set of effector proteins 
and, thereby, regulates a characteristic suite of cellular 
processes, including membrane trafficking, cell 
survival/growth, cell division, and cellular motility [28] 
(See also Figure 5). Importantly, aberrant lipid 
metabolism often leads to the onset of pathology, and 
thus the precise balance of signaling lipids and their 
effectors can serve as biomarkers for health and disease 
[19,22,27]. Therefore, the increased intracellular levels 
of PI(3,5)P2 that result from either MIP ablation or 
from the natural decrease in MIP function with aging 
might induce significant imbalances in signaling 
pathways.  
The potent signaling properties of PIPs depend on their 
localization as well as abundance, which are determined 
by the collective actions of PIP kinases, PIP 
phosphatases, and phospholipases [29,30]. PIP 
phosphatases (such as MIP) are a subfamily of 
phosphatases that hydrolyze PIPs [31] (Figure 5). For 
example, PTEN phosphatase dephosphorylates 
PI(3,4,5)P3 on the plasma membrane and is critical for a 
variety of cellular processes [32].  Loss of PTEN 
function is associated with the tumorigenesis of many 
types of cancers [32]. The role of other PIP phosphatases, 
such as myotubularin- and myopathy- related 
phosphatases (MTMR) have not been well characterized.  
PIPs are also involved in bipolar disorder, myopathies, 
acute myeloid leukemia, and type-2 diabetes. 
Importantly, loss-of-function mutations in several 
MTMR phosphatases (MTM1, MTMR2, and MTMR13) 
have been identified in genetic conditions, namely X-
linked myotubular myopathy (a muscle degenerative 
disease that shares some similarities with sarcopenia) and 
Type-4B Charcot-Marie-Tooth disease (a neuro-
degenerative condition) [33-36]. However, the molecular 
mechanisms by which the mutations in these 
phosphatases induce such diseases remain largely 
unknown [19,24].  As shown in Figure 5, the quick 
interconversion of seven different PIPs creates a dynamic 
signaling network that might underlie molecular 
mechanisms relevant for a myriad of diseases.  
 
We believe that aging must be seen as the result of a 
multitude of long-term, cumulative adaptations and not 
only due to changes resulting from the ablation or the 
downregulation of a single gene. Nevertheless, changes 
in MIP function could cause a cascade of effects with 
consequences that could be far more serious and 
broader than the specific change in MIP itself. The 
reason for such assertion is rather simple. MIP controls 
the intracellular levels of PI(3,5)P2, which in turn binds 
to a multitude of proteins [28-30], therefore working as 
a principal molecule in the coordination of intracellular 
networks [28,31]. Intriguingly, we have recently 
obtained preliminary evidence that indicates that mature 
MIPKO develops cardiovascular diseases and 
osteoporosis, both in agreement of a broader and age-
related role of MIP (Wacker, Andresen, Bonewald, 
Johnson & Brotto; unpublished observations). 
Furthermore, we previously showed that intracellular 
elevation of PI(3,5)P2 is able to activate the opening of 
the RyR1 at contracting or resting levels of Ca
2+. Such 
an effect can lead to a vast amount of secondary 
changes as Ca
2+  itself is a second messenger that 
controls cellular life and death. For example, 
chronically elevated resting levels of intracellular Ca
2+ 
as observed in mature MIPKO and old Wt muscle cells, 
might activate proteolytic enzymes or enhance the 
Figure 4. Altered Ca
+2 homeostasis is present in muscle
fibers  from  old  Wt  and  MIPKO  mice.  Original  traces
representative  of  caffeine‐induced  Fura‐2  Ca
+2  transients  in
mature Wt (black trace), old Wt (red trace), and mature MIPKO
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which in turn may contribute to muscle wasting.  
 
In summary, our studies suggest new roles of MIP and 
its major substrate, PI(3,5)P2, in the decline in muscle 
function during aging. We believe that the loss of MIP 
activity with age could contribute to the loss of muscle 
function due to the buildup of PI(3,5)P2 within the 












































conductance of the ryanodine receptor channel, loss of  
Ca
2+ from the SR, and also inhibition of SOCE into the 
cell [16]. While additional studies will be required to 
better define the cell biological functions of MIP and 
PI(3,5)P2, we propose that the MIP-PI(3,5)P2 
signaling pathway is an important contributor for 
aging sarcopenia, and as such could be explored as a 
new therapeutic option for the treatment of not only 
muscle myopathies, but also for aging sarcopenia. In 
addition, the MIPKO model seems suitable for 
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Force Plate Actimeter (FPA). To complement our in 
vivo muscle function approaches we have selected the 
FPA because it provides an efficient, accurate, and 
highly reproducible means of assessing many aspects of 
locomotor behavior [17].  
 
Ex-vivo, isolated muscle contractility protocols. These 
studies followed protocols established by Brotto & 
Nosek [37-39]. Intact extensor digitorum longus (EDL) 
muscle of male and female WT and MIPKO mice of all 
age groups were removed from tendon to tendon and 
immediately placed in a dissecting dish containing a 
modified bicarbonate Ringer solution with 2.5 mM 
extracellular Ca
2+ or with 0 mM Ca plus 0.1 mM EGTA 
to test the effects of extracellular Ca
2+ and SOCE in 
muscle function. The pH was adjusted to 7.4 with 
NaHCO3, followed by the addition of fetal bovine 
serum (to 0.2%) to increase viability of the dissected 
muscle [37,40].  The solution was continuously aerated 
with a gas-mixture consisting of 95% O2 and 5% CO2. 
EDL and SOL muscles were mounted vertically 
between two Radnoti (Monrovea, CA, USA) 
stimulating platinum electrodes and immersed in a 20 
ml bathing chamber containing the incubation medium. 
Via the tendons, the muscles were suspended from 
movable isometric force transducers above the 
chambers and secured to the base of the tissue support 
within the chambers.  The analog output of the force 
transducer were digitized, stored and analyzed with 
PowerLab Software (Colorado Springs, CO, USA).  For 
each muscle, the resting tension and the stimulatory 
voltage was provided by a Grass S8800 digital 
stimulator (West Warwick, RI, USA) and adjusted to 
produce a maximal isometric tetanic force (Tmax). EDL 
muscles were the muscle choice since effects of 
Sarcopenia are known to be exacerbated in fast-twitch 
muscles such as the EDL. Equilibration: The intact 
muscles were allowed a 20-minute equilibration period 
after which time they were stimulated with pairs of 
alternating high (that produced Tmax) and low (that 
produced 1/2 Tmax) frequency pulse-trains administered 
with a periodicity of 1 minute.  Utilization of the 
proposed paradigm of stimulation helps with the study 
of the relative contributions of the contractile proteins 
(Tmax) and the SR (1/2 Tmax) to contractile function [37).  
 
Force vs. frequency relationship. Following 
equilibration, the muscles are subjected to stimulation 
with frequencies ranging from 1-200 Hz to generate the 
force vs. frequency (FF) relationship. Force 
Normalization: All force data are normalized as either 
the absolute force (force per cross sectional area) or as a 
percentage of the maximum tetanic force (%Tmax) 
measured before the beginning of the fatiguing protocol. 
 
Fura-2 monitoring of intracellular Ca
2+. For quantitative 
measurements of intracellular [Ca
2+], flexor digitorum 
brevis (FDB) muscle
 fibers were utilized. FDB muscle 
fibers were enzymatically isolated in a 0 Ca Tyrode 
solution containing 2 mg/mL type I collagenase for 2 
hours in a shaking bath at 37°C. FDB muscle fibers 
were then transferred to a 0 Ca
2+ Tyrode solution 
without collagenase and gently triturated with a pipette.  
The fibers were then be loaded with 5 µM Fura-2-AM 
for 40 minutes, after which the Fura-2 AM was washed 
off and be allowed to de-esterify. As fiber motion 
artifacts are associated with intracellular Ca
2+ release, 
20  μM N-benzyl-p-toluene sulfonamide (Sigma), a 
specific myosin II inhibitor, was then applied for 20 
minutes.  A dual-wavelength
 (excitation at 340 nm and 
380 nm) PTI spectrofluorometer (Photon
  Technology 
International, Birmingham, NJ) was used to determine
 
the magnitude and kinetic changes of caffeine-induced 
intracellular Ca
2+ transients. Ratiometric changes were 
converted into relative levels of Ca
2+ i n  n M  a s  
previously detailed by Brotto et al [41]. 
 
Biochemical profiling of skeletal muscles. Freshly 
isolated EDL muscles were dissected from all mice and 
saved for biochemical analyses. Gene expression, MIP 
protein content, and MIP activity assays were 
performed on these muscles as previously described by 
Zhao et al. [11] and recently modified by Shen et al 
[16]. 
 
MIP gene expression and MIP protein expression. 
These procedures were performed as described in Zhao 
et al, and as recently modified in Shen et al [16]. 
Briefly, the mRNA expression level of MIP gene was 
determined by qPCR in freshly isolated EDL muscles 
after mRNA was extracted using a RNeasy mini kit 
(Qiagen, Valencia, CA, USA) and transcribed into 
cDNA by M-MLV Reverse Transcriptase (Promega, 
Madison, WI, USA).  qPCR was performed using 
SYBR Green PCR supermix (Invitrogen, Carlsbad, CA, 
USA) on a Bio-Rad MyIQ 96-well PCR detection 
system. The glyseraldehyde-3-phosphate dehydrogenase 
(GAPDH) gene was used as the reference gene. Quality 
of the amplicons was confirmed by detection of uniform 
melting curve peaks for each gene. One hundred 
nanograms of cDNA were added per reaction and the 
final primer concentration was 200 nM. Experiments 
were run in triplicate. Relative Ct values were 
calculated as 2
CtGAPDH–CtTarget. Protein concentrations 
were determined by DC protein assay (Bio-Rad) and 10 
μg per sample was separated by SDS–polyacrylamide gel 
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glycine gradient gels for 2h at 60 mAmps on a Mini 
PROTEAN II gel system (Bio-Rad). Gels were loaded 
in parallel and one set was stained with Novex Colloidal 
Blue stain (Invitrogen), per manufacturer’s instructions. 
Equivalent loading was confirmed using monoclonal β-
actin antibody (Sigma), 0.2 μg mL−1. Results were 
visualized with an ECL + kit (GE Healthcare, 
Piscataway, NJ, USA) following the manufacturer’s 
directions.  
 
MIP phosphatase activity. To determine the lipid 
phosphatase activity, Di-C8 phosphoinositides (Echelon 
Biosciences Inc., Salt Lake City, UT) and dioleoyl-
phosphatidylserine (Sigma, St. Louis, MO) were 
resuspended via sonication in the assay buffer (100 mM 
sodium acetate, 50 mM bis-Tris, 50 mM Tris pH 5.5, 
and 10 mM dithiothreitol) to final concentrations of 100 
and 1000 μM, respectively. Equal volumes of di-C8 
phosphoinositides and dioleoyl-phosphatidylserine were 
added into 1.5 ml microcentrifuge tubes and the 
mixtures were prewarmed at 37°C for 5 min. Reactions 
were initiated by the addition of 500 ng of GST-MIP 
fusion protein diluted in the assay buffer containing 1.0 
mg/ml gelatin. This reaction step provided the control 
values seen in Figure 4. Next, muscle homogenate 
reactions were initiated by the addition of 2000 ng of 
total muscle protein diluted in the assay buffer 
containing 1.0 mg/ml gelatin. Reactions were quenched 
after 30 min by the addition of 20 μl of 0.1 M N-
ethylmaleimide and spun at 18,000 × g for 10 min to 
sediment the lipid aggregates.  The supernatant (25 μl) 
was added to a 96-well plate and 100 μl of Malachite 
green reagent (Echelon Biosciences Inc., Salt Lake City, 
UT) was added to each well.  After incubation at room 
temperature for 15 min, the color development was 
measured at 620 nm.  Inorganic phosphate release was 
quantitated using a standard curve generated with 
KH2PO4 in distilled H2O.  
 
Statistical analyses. Values are mean ± SEM. 
Significance was determined by ANOVA followed by 
either Tukey's or Bonferroni's tests. ANOVA on Ranks 
followed by Kruskal-Wallis test was used for non-
parametric data. A value of P < 0.05 was used as 
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